A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Study Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Conditions

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Follicular Lymphoma (FL)Diffuse Large B-cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)

Interventions / Drugs

NX-2127

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment248 participants

Primary Completion—

Lead SponsorNurix Therapeutics, Inc.

Data Retrieved2026-04-11 04:22:54.408658+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.